Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …

Shabnam Jaffer

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond

2024 ESMO Annual Meeting Insights Hub

L. Carey

ESMO 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

Brief Update on Genomic Assays for Early Stage Breast Cancer

Adam Brufsky

ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer

2024 ESMO Annual Meeting Insights Hub

J. Huober

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

Benefits of Oral Formulations in HR+/HER2- mBC: Reducing Time Toxici…

Priya Tiwari

monarchE Study: The Impact of Dose Reductions on Abemaciclib Efficac…

Miguel Abreu

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy